Competition is exceedingly high within the pharmaceutical and biotechnology industry whereby quality standards are thus reprehended. This requires constant supervision and investigation of processes involved in the production of drugs and related products.
Process capability analysis and Annual Product Quality Review (APQR) are two critical tools that, when integrated, provide a comprehensive view of manufacturing performance. Process capability indices like Cp, Cpk, Pp, and Ppk quantify how well a process meets specifications, while APQR consolidates annual data to identify trends and areas for improvement.
By integrating these approaches, pharmaceutical companies can move from reactive quality management to proactive process optimization. Statistical process control charts, trend analysis, and capability assessments become part of a unified quality intelligence platform.
The benefits include early detection of process drift, reduced batch failures, streamlined regulatory submissions, and data-driven decision making for continuous improvement initiatives.
